Liver disease is associated with various chronic aftermaths and can be damaged by several sources ranging from hepatitis C and excessive consumption of alcohol.
Liver cirrhosis is the most common type prolonged damage to the liver.
And the disease is characterized by the formation of fibrous scar tissue, which inhibits the ability of the liver to add and remove substances from the blood. Patient with advanced liver cirrhosis is reported to be associated with hypotension and endotoxemia, which indicates the involvement of the endocannabinoid.
According to the research conducted by Tam, Joseph et al. (2011) suggest that the high hypotensive action of the CBD has been assumed to be used in the further treatment of hypertension. This is the same effect that synthetic cannabinoid has when triggered under the cardiovascular system. Research suggests that cirrhosis in rats is characterized by progressive hypotension, which can be reversed by the CB1 blockage. Also, the presence of endocannabinoids in the liver at the concentration at similar to those in the brain stimulates the inhibition of the liver stellate cells which generate scars issues. On the other hand, CB2 receptors that are frequently undetected in the liver and permanently expressed in the cirrhotic human liver. In effect, the CBD derived from hemp suppresses the proliferation and regenerated apoptosis of human hepatic myofibroblast and stellate cells through CB2 receptors and; hence may become be anti-fibrotic and hepatoprotective (Tam, Joseph et al., 2011).
Separately, endocannabinoids are also reported to be involved in the diet-induced decrease in fatty-acid oxidation. In this case, the liver fat accumulation can be regulated hepatic carnitine palmitoyltransferase-1. Finally, because ECS is present in the liver, it has been argued that is it has a various function in the therapeutic implications. Moreover, increased activity of CB1 receptors in the liver contributes to the hemodynamic abnormalities and promotes fibrosis in the liver cirrhosis. Additionally, non-psychoactive CB2 agonists may offer therapeutic benefit in attenuating liver injury and promoting tissue repair in the fibrotic liver (Alswat, 2013).
Tam, J., Liu, J., Mukhopadhyay, B., Cinar, R., Godlewski, G., & Kunos, G. (2011). Endocannabinoids in Liver Disease. Hepatology (Baltimore, Md.), 53(1), 346–355. http://doi.org/10.1002/hep.24077
Alswat, K. A. (2013). The Role of Endocannabinoids System in Fatty Liver Disease and Therapeutic Potentials. Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association, 19(4), 144–151. http://doi.org/10.4103/1319-3767.114505